Technology Innovation Institute Appoints Eminent Technologist Dr Ray O. Johnson as CEO
2.8.2021 16:54:00 EEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), the overarching advanced technology body in Abu Dhabi responsible for driving research and development for transformative technology outcomes, today announced the appointment of veteran technologist and entrepreneur Dr Ray O. Johnson as Chief Executive Officer. Dr Johnson will work on shaping the strategic direction of the Institute and lead the execution of its growth strategies to achieve operational excellence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005462/en/
Dr Ray O. Johnson, Chief Executive Officer, Technology Innovation Institute (Photo: AETOSWire)
Prior to joining TII, Dr Johnson was an Operating Partner at Bessemer Venture Partners, a top-tier American venture capital company that has been part of 130 IPOs in the last 50 years, and before that, he was the Corporate Senior Vice President for Engineering, Technology, and Operations and Chief Technology Officer of the Lockheed Martin Corporation.
Dr Johnson brings to his role over four decades of experience in global technology leadership, making strategic investments in disruptive technologies, and developing business strategies that resulted in several new billion-dollar lines of business. He also holds outstanding networking capabilities; he has met with leaders at the highest echelons of government, industry, and academia. He is frequently sought after as a speaker at global forums on business, strategy, innovation, and education.
Speaking on the new appointment, His Excellency Faisal Al Bannai, Secretary General of ATRC, said: “We welcome Dr Ray Johnson as the first CEO of Technology Innovation Institute. His appointment is a much anticipated one – we were keen that the person entrusted with this role should not merely be an excellent research and technology specialist, but equally, a consummate professional and industry stakeholder that is capable of ensuring the most positive outcomes for the breakthrough projects TII is currently engaged in across its seven initial dedicated research centres.
“We are confident Dr Johnson will be able to build game-changing synergies for TII as he leads it towards realising its wider goals of growing its talented global team of 375+ researchers, scientists, and engineers, and ensuring the objectives of the current workstreams are met. He will also leverage his vast network to further expand our visibility and reach across markets.”
For his part, Dr Ray O. Johnson said: “I am very excited about this new role in a region that I admire for its dedication to advanced research and development for the betterment of the UAE. Since TII’s inception in November 2020, I have followed its many announcements and achievements with great interest. As it moves into a new phase of growth, I look forward to working with the talented teams of researchers across its centres to drive competitive results and facilitate breakthrough solutions that transition to the market.”
Technology Innovation Institute (TII) is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy, and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE, reinforces the status of Abu Dhabi and the UAE as a global hub for innovation, and contributes to the broader development of the knowledge-based economy.
For information on Advanced Technology Research Council (ATRC), visit www.atrc.ae
For information on Technology Innovation Institute (TII), visit www.tii.ae
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005462/en/
Contact information
Technology Innovation Institute
Hanz Valbuena
hanz.valbuena@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 11:00:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Gi
Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 11:00:00 EEST | Press release
Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasing demand for AI, but for managed services, which acts as a cost-savings lever to help fund AI ambitions and continued digital
Maureen Mahr von Staszewski Joins Heitman European Leadership Team13.7.2026 10:30:00 EEST | Press release
Heitman LLC (“Heitman”), a global real estate investment management firm, today announced the appointment of Maureen Mahr von Staszewski as Managing Director in the firm’s European Real Estate Investment team. As part of Heitman’s European leadership team, Maureen will help drive continued expansion across Europe, supporting the firm’s strategic growth initiatives, capital raising efforts, and investment activity across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713202147/en/ Maureen Mahr von Staszewski Joins Heitman European Leadership Team “We are excited Maureen has joined the Heitman team,” said Caleb Mercer, Managing Director and Head of European Investment at Heitman. “Her breadth and depth of experience in European real estate investment management will help strengthen our innovative and differentiated investment capabilities across traditional and alternative property types throughout Europe.” In h
LTM Partners with Anthropic to Accelerate Claude Adoption and Expand Enterprise Delivery13.7.2026 09:16:00 EEST | Press release
LTM, the Business Creativity partner to the world's largest enterprises, today announced a partnership with Anthropic, the frontier AI company behind Claude, to accelerate enterprise-scale adoption of Claude, Claude Code and Claude Cowork across engineering, modernization, and business workflows. LTM will combine Claude, Claude Code and Claude Cowork with its enterprise implementation expertise to help clients move from pilots to production with market-leading productivity, throughput, quality underscored by assurance and transparency. LTM will specifically bring this expertise and capability to BFSI, Hi-Tech, Consumer and Production Industry domains. The three strategic focus areas of partnership include: LTM BlueVerse™: AI Delivery Fabric LTM BlueVerse AI Delivery Fabric will serve as the enterprise implementation layer for Claude adoption, integrating Claude and Claude Code into delivery workflows across AI-led software engineering, application modernization, agent orchestration, Si
Sofinnova Partners Appoints David Evans as Partner13.7.2026 09:00:00 EEST | Press release
Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-sciences investing. Evans’s breadth of experience, anchored in hands-on pharma expertise, contributes complementary expertise to Sofinnova's Crossover Strategy. Evans will play a key role in the Strategy’s late-stage private and public life-sciences investments. His combination of clinical, scientific, and investment expertise strengthens the firm's ability to evaluat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom